Cagrilintide vs SNAP-8
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Cagrilintide
Cagrilintide is a long-acting amylin analog in development, showing promising results when combined with semaglutide (CagriSema). Amylin is a hormone co-secreted with insulin that promotes satiety.
Full details →SNAP-8
SNAP-8 (Acetyl Octapeptide-3) is a cosmetic peptide that reduces the appearance of wrinkles by modulating muscle contraction. It is often called 'topical Botox' though it works through a different mechanism.
Full details →Side-by-Side Comparison
| Aspect | Cagrilintide | SNAP-8 |
|---|---|---|
| Mechanism | Activates amylin receptors (calcitonin receptor with RAMP proteins) to slow gastric emptying, suppress glucagon secretion, and reduce food intake through central satiety mechanisms distinct from GLP-1. | Mimics the N-terminal end of SNAP-25, competing with native SNAP-25 for position in the SNARE complex. This reduces neurotransmitter release at the neuromuscular junction, decreasing muscle contraction. |
| Typical Dosage | Clinical trials: 2.4mg weekly as monotherapy or in combination with semaglutide 2.4mg (CagriSema). Optimal dosing still being determined. | Topical: 3-10% concentration in serums or creams, applied 1-2 times daily to target areas (forehead, crow's feet, etc.). |
| Administration | Subcutaneous injection once weekly. Currently only available in clinical trials - not yet FDA approved. | Topical application only. Should be applied to clean skin. Often formulated with penetration enhancers for better absorption. |
| Side Effects | Nausea, vomiting, diarrhea, constipation similar to other incretin-based therapies. Combination with semaglutide may increase GI effects initially. | Generally well-tolerated topically. Rare reports of mild skin irritation. No systemic effects at cosmetic doses. |
| Best For |